Regulatory Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC Pharmaceutical TechnologyThe EMA's CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories' Braftovi to treat mCRC with BRAFV600E mutations.OncologyRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) Pharmaceutical Technology The EMA’s CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations. Oncology Read full story Post navigation Previous: All eyes on Revolution, bispecific antibodies and more at ASCO26Next: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026